Skip to content
value.today
Seer Biosciences, Inc. logo

Seer Biosciences, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2017
Total raised
$6 M
1 round on record
Latest round
$6 M
Dec 2017
First round on record
Dec 2017
Today
Went public
See the company page

Seer Biosciences, Inc. is listed today as Seer, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Seer Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2017$6 MNo. 1$2 to $10 million

Seer Biosciences, Inc.: Raise no. 1, Dec 2017

Investors in this round

11 investors had bought by the notice of Jan 4, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Seer Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$425,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Philip Ma · Executive Officer
  • Shadi Aryanpour · Executive Officer
  • David Singer · Director
  • Omid Farokhzad · Director
  • Robert Langer · Director
  • Terrance McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the directors and officers of the Issuer listed in Item 3 will receive compensation in connection with their service or employment with the Issuer.”

Signed by Philip Ma, President and Chief Business Officer. Source: SEC Form D, newest notice filed Jan 4, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Seer Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2018).

    SEC Form D · Jan 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2018

That is all the official record says: Seer Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Seer Biosciences, Inc. are on record.

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in Seer Biosciences, Inc.
InvestorKindAmountRoundRoleSource
aMoon 2 Fund Limited PartnershipFund or asset managernot statednot statedHeld Series D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Artal Group S.A.Fund or asset managernot statednot statedHeld Series B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Artal International Management S.A.Fund or asset managernot statednot statedHeld Series B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Artal Treasury LtdCompanynot statednot statedHeld Series B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Invus Public Equities Advisors, LLCFund or asset managernot statednot statedHeld Series B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Invus Public Equities, L.P.Fund or asset managernot statednot statedHeld Series B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Maverick Advisors Fund, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Maverick Capital Ventures, LLCVenture capitalnot statednot statedHeld Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Maverick Ventures Investment Fund, L.P.Venture capitalnot statednot statedHeld Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Omead OstadanPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2020)SEC Form 3
Robert LangerPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2020)SEC Form 3
Westend SACompanynot statednot statedHeld Series B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.

Largest shareholders today

Institutions holding Seer, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Seer Biosciences, Inc.
NameRoleNamed in
Philip MaExecutive officerJan 2018
Shadi AryanpourExecutive officerJan 2018
David SingerDirectorJan 2018
Omid FarokhzadDirectorJan 2018
Robert LangerDirectorJan 2018
Terrance McGuireDirectorJan 2018

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.